2017
DOI: 10.1016/j.jcf.2016.12.008
|View full text |Cite
|
Sign up to set email alerts
|

Chest imaging in cystic fibrosis studies: What counts, and can be counted?

Abstract: Background The dawn of precision medicine and CFTR modulators require more detailed assessment of lung structure in cystic fibrosis (CF) clinical studies. High-resolution chest computed tomography (CT) scoring has yielded sensitive markers for the study of CF disease progression and therapeutic effectiveness. Similarly, Magnetic Resonance Imaging (MRI) is in development to generate structural as well as functional markers. Results The aim of this review is to characterize the role of CT and MRI markers in cl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
52
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 48 publications
(52 citation statements)
references
References 52 publications
0
52
0
Order By: Relevance
“…Second, this study is limited by the lack of chest imaging studies. Future studies including chest CT or magnetic resonance imaging outcome measures [39,40] will be critical to specify and localise the structural abnormalities associated with surface-bound NE that determine lung function decline and pulmonary hyperinflation. Third, established surveillance programmes in infants and young children with CF that include annual BAL will provide opportunities to determine the role of this cell-bound pool of NE in early CF lung disease, where structural lung disease can occur even in the absence of free NE activity in BAL fluid [1,2].…”
Section: Discussionmentioning
confidence: 99%
“…Second, this study is limited by the lack of chest imaging studies. Future studies including chest CT or magnetic resonance imaging outcome measures [39,40] will be critical to specify and localise the structural abnormalities associated with surface-bound NE that determine lung function decline and pulmonary hyperinflation. Third, established surveillance programmes in infants and young children with CF that include annual BAL will provide opportunities to determine the role of this cell-bound pool of NE in early CF lung disease, where structural lung disease can occur even in the absence of free NE activity in BAL fluid [1,2].…”
Section: Discussionmentioning
confidence: 99%
“…Despite this, FEV 1 presently is used to guide therapy . While other modalities to monitor CF lung disease are emerging, further optimization is required for these complex approaches …”
Section: Introductionmentioning
confidence: 99%
“…13 Despite this, FEV 1 presently is used to guide therapy. 9 While other modalities to monitor CF lung disease 14 are emerging, further optimization is required for these complex approaches. 15 It is thus evident that rapid, cost-effective, and informative strategies for lung ventilation evaluation in CF patients are urgently required.…”
Section: Introductionmentioning
confidence: 99%
“…Chest computed tomography (CT) scans are the most sensitive marker of lung disease in infancy . However, routine surveillance CT scans are currently used largely in research only.…”
Section: Introductionmentioning
confidence: 99%